Analysis reveals underreporting of aesthetic Botulinum Toxin Type A adverse events, suggesting safety improvements are needed globally.
The predominance of effectiveness issues over traditional safety concerns distinguishes aesthetic BoNT-A pharmacovigilance from typical pharmaceutical surveillance. Geographic concentration of reporting in the United States despite global market distribution indicates systematic underreporting internationally. These findings suggest current pharmacovigilance systems inadequately capture aesthetic medicine adverse events, with direct implications for patient safety and regulatory oversight.
No takes yet. Share an insight, caveat, or question.
Zargaran et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: